TABLE II.

Multivariable Analyses of AXIN2 in Validation Cohorts

Thomas Jefferson University —Biochemical recurrence			Mayo Clinic Registry—Distant metastasis
	OR (97.5%CI)	P-value		OR (97.5%CI)	P-value
AXIN2 expression	0.13 (0.02–0.67)	0.020	AXIN2 expression	0.33 (0.12–0.83)	0.015
Gleason 7	3.29 (0.75–23.11)	0.15	Gleason 7	1.90 (0.71–5.87)	0.23
Gleason ≥8	5.71 (1.20–42.32)	0.046	Gleason ≥8	4.90 (1.77–15.55)	0.0037
pT3a	2.06 (0.63–7.66)	0.025	pT3a	1.07 (0.66–1.73)	0.78
pT3b	1.44 (0.59–3.53)	0.42	pT3b	1.45 (0.86–2.45)	0.16
			Lymph node positive	1.23 (0.63–2.39)	0.55
Positive surgical margins	1.00 (0.37–2.76)	0.99	Positive surgical margins	0.56 (0.34–0.90)	0.019
PSA 10–20	1.44 (0.49–4.25)	0.51	PSA 10–20	0.59 (0.32–1.05)	0.073
PSA > 20	2.36 (0.66–9.25)	0.20	PSA > 20	0.57 (0.32–1.01)	0.056
Administration of ADT	2.71 (1.02–7.47)	0.048	Administration of ADT	16.78 (9.31–31.90)	<0.001
			Administration of radiotherapy	4.05 (2.36–7.12)	<0.001

Association of low AXIN2 expression with clinical outcomes (left, TJU: biochemical recurrence; right, MC: distant metastasis), after adjustment for other clinical variables known to impact recurrence.